| Date | Title | | | December 31, 2015 | BeyondSpring Pharmaceuticals Granted CTA by CFDA to initiate China Arm of Global Phase III Trial of Lead Asset Plinabulin |  | | November 17, 2015 | BeyondSpring Data Demonstrating Activity of Plinabulin in Kras-Mutant Tumors Presented at AACR-NCI-EORTC International Conference 2015 | | | October 30, 2015 | BeyondSpring Announces Appointments of Dr. Ramon Mohanlal as Chief Medical Officer and Robert Dickey IV as Chief Financial Officer | | | September 15, 2015 | BeyondSpring Announces Positive Follow-Up Results for Phase 2 Trial of Plinabulin in Advanced NSCLC at WCLC 2015 | | | September 15, 2015 | BeyondSpring Announces Planned Start of Phase I Investigator-Initiated Trial of Plinabulin Plus Nivolumab, Enters Immuno-Oncology Space | | | September 1, 2015 | Data Supporting BeyondSpring’s lead asset, Plinabulin, to be presented at WCLC 2015 | | | August 31, 2015 | BeyondSpring to Present Two Posters Supporting Plinabulin at WCLC 2015 | | | March 23, 2015 | BeyondSpring Extends Plinabulin IP Portfolio with Two New Methods of Treatment Patent Applications | | | February 24, 2015 | BeyondSpring Files Composition of Matter Patent Application for Plinabulin Combination Therapy in Immuno-Oncology | |
|
Print Page | 
Email Page | 
RSS Feeds | 
Email Alerts | 
Contact IR | 
Financial Tear Sheet
